RxDoctor Payments Data

Casey Sullivan

Family · Hagerstown, MDNPI 1457015372

Payments from drug & device makers

$1,289in general payments, 2019–2025

Across 74 payments — averaging $17.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$434
  • GSK$327
  • Boehringer Ingelheim$122
  • Inspire Medical Systems, Inc.$98
  • Electromed, Inc.$84
  • Amgen$79
  • plus $145 from 5 others

What the payments were for

  • Food & beverage$1,289100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,289 in reported general payments places this provider in the 75th percentile of 2,843 family providers in Maryland.

See all family providers in Maryland

Medicare billing

Part B allowed, 2024
$60,956
Medicare patients
333
Services billed
811

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter521$498,822
OfevNintedanib Esylate16$274,641
Breztri AerosphereBudesonide/Glycopyr/Formoterol137$98,067
Spiriva RespimatTiotropium Bromide105$83,663
Incruse ElliptaUmeclidinium Bromide119$66,467
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr81$65,569
Breo ElliptaFluticasone/Vilanterol102$62,359
Fluticasone-SalmeterolFluticasone Propion/Salmeterol169$27,247
Stiolto RespimatTiotropium Br/Olodaterol Hcl29$23,145
Advair HfaFluticasone Propion/Salmeterol64$22,142
Albuterol Sulfate HfaAlbuterol Sulfate669$19,212
Spiriva HandihalerTiotropium Bromide18$14,737
DuleraMometasone/Formoterol35$14,013
Bevespi AerosphereGlycopyrrolate/Formoterol Fum26$12,935
Arnuity ElliptaFluticasone Furoate38$11,640

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Incruse Ellipta, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta$327$704,856861 claims
Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat$122$381,449150 claims
AstraZenecaBreztri Aerosphere, Bevespi Aerosphere, Symbicort$434$119,764185 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,843 family providers in Maryland.

Other family in Hagerstown

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →